Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05237947 | Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial(PRISMA) | active not recruiting | Phase 4 | 5,000 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06908694 | Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy(GAINPCCONTROL) | active not recruiting | Phase 4 | 20 | Hamilton Health Sciences CorporationOTHER |
| 1 |
| Sep 14, 2026 |
| clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05722925 | Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET | active not recruiting | Phase 4 | 50 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03016741 | Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | active not recruiting | Phase 4 | 100 | Northwestern UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06627530 | COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer(COAction) | active not recruiting | Phase 4 | 144 | Brazilian Clinical Research InstituteOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06479187 | PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer | active not recruiting | Phase 4 | 20 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT06074510 | PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer(MIRROR) | active not recruiting | Phase 4 | 274 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT03180034 | Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study(ESCUDDO) | active not recruiting | Phase 4 | 27,945 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06972693 | NGS-based Germline and Somatic Genetic Test in Ovarian Carcinoma(PERSONA-Ovary) | active not recruiting | Phase 4 | 323 | European Institute of OncologyOTHER | 1 | May 15, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 21, 2026source: clinicaltrials